Topic: Boston

Industry-paid studies likely to favor company drug

NEW YORK (Reuters Health) - When drugmakers fund studies of their own products, the results are much more likely to be positive than when the government picks up the bill, US researchers said Monday. They found that about 85 percent of industry-backed ...

Special Report: Inside the battle for Genzyme's future

BOSTON (Reuters) - At a recent dinner to honor the achievements of Henri Termeer, chief executive of biotechnology company Genzyme, Ananth Raman broke down as he recalled the moment he learned his 7-month old daughter had Pompe disease, a rare genetic disorder ...
Struggling US biotech firm Epix Pharma liquidating assets to pay off creditorsEpix, a struggling biotechnology firm working with British drug maker GlaxoSmithKline PLC to develop an Alzheimer's disease drug, says it is winding down its operations and selling off assets to pay ...

Practicing good medicine

Doctors should learn to rely less on manufacturers’ sales pitches when prescribing drugs If you have visited a doctor’s office lately, chances are you have seen pens, coffee mugs and other trinkets that advertise a particular drug. Pharmaceutical companies spend billions of ...